Literature DB >> 25182853

(11)C-choline PET/CT tumor recurrence detection and survival prediction in post-treatment patients with high-grade gliomas.

Wanhu Li1, Li Ma, Xiaoyue Wang, Jujie Sun, Suzhen Wang, Xudong Hu.   

Abstract

The aim of the present study is to evaluate the role of (11)C-choline positron emission tomography/computed tomography (PET/CT) in detecting tumor recurrence and predicting survival in post-treatment patients with high-grade gliomas. A total of 16 previously treated histopathologically proven high-grade glioma patients were subjected to (11)C-choline PET/CT scan and survival analysis. We found that the sensitivity and specificity of (11)C-choline PET/CT were 100 and 70 %, whereas those of Gd-MRI were 83.3 and 60 %, respectively. By Cox regression analysis, (11)C-choline T/N ratio correlated obviously with overall survival (OS) (hazard ratio = 2.644, 95 % confidence interval [CI] = 1.027-6.807, p = 0.044) independent of Karnofsky performance score. Patients with lower T/N ratio (tumor uptake/normal brain tissue uptake) (≤1.42) had longer survival times than patients with higher T/N ratio (median OS = 15.4 vs. 5.3 months, p < 0.001; progression-free survival (PFS) =4.5 vs. 0.8 months, p = 0.004). Thus, this preliminary study suggests that (11)C-choline PET/CT is highly sensitive in detecting tumor recurrence in post-treatment patients with high-grade gliomas. Moreover, our preliminary results suggest that T/N ratio measured by (11)C-choline maybe serves as a predictor of patients' survival with suspected recurrent glioma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25182853     DOI: 10.1007/s13277-014-2549-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  23 in total

1.  Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.

Authors:  Marc C Chamberlain; Michael J Glantz; Lisa Chalmers; Alixis Van Horn; Andrew E Sloan
Journal:  J Neurooncol       Date:  2006-08-31       Impact factor: 4.130

2.  Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients.

Authors:  Ken Herrmann; Johannes Czernin; Timothy Cloughesy; Albert Lai; Kelsey L Pomykala; Matthias R Benz; Andreas K Buck; Michael E Phelps; Wei Chen
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

Review 3.  New advances that enable identification of glioblastoma recurrence.

Authors:  Isaac Yang; Manish K Aghi
Journal:  Nat Rev Clin Oncol       Date:  2009-10-06       Impact factor: 66.675

Review 4.  New PET radiopharmaceuticals beyond FDG for brain tumor imaging.

Authors:  B Gulyás; C Halldin
Journal:  Q J Nucl Med Mol Imaging       Date:  2012-04       Impact factor: 2.346

Review 5.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.

Authors:  Dieta Brandsma; Lukas Stalpers; Walter Taal; Peter Sminia; Martin J van den Bent
Journal:  Lancet Oncol       Date:  2008-05       Impact factor: 41.316

6.  PET imaging of prostate cancer using carbon-11-choline.

Authors:  T Hara; N Kosaka; H Kishi
Journal:  J Nucl Med       Date:  1998-06       Impact factor: 10.057

7.  18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT.

Authors:  Sellam Karunanithi; Punit Sharma; Abhishek Kumar; Bangkim Chandra Khangembam; Guru Pada Bandopadhyaya; Rakesh Kumar; Deepak Kumar Gupta; Arun Malhotra; Chandrasekhar Bal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-03-23       Impact factor: 9.236

8.  A comparative study on the uptake and incorporation of radiolabeled methionine, choline and fluorodeoxyglucose in human astrocytoma.

Authors:  T K Narayanan; Sinan Said; Jogeshwar Mukherjee; Brad Christian; Martin Satter; Kelly Dunigan; Bing Shi; Martin Jacobs; Theodore Bernstein; Madakasira Padma; Joseph Mantil
Journal:  Mol Imaging Biol       Date:  2002-03       Impact factor: 3.488

9.  Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas.

Authors:  J Nuutinen; S Leskinen; P Lindholm; K O Söderström; K Någren; S Huhtala; H Minn
Journal:  Eur J Nucl Med       Date:  1998-07

Review 10.  Pseudoprogression in high-grade glioma.

Authors:  K M Knudsen-Baas; G Moen; Ø Fluge; A Storstein
Journal:  Acta Neurol Scand Suppl       Date:  2013
View more
  5 in total

Review 1.  Positron emission tomography of high-grade gliomas.

Authors:  Guido Frosina
Journal:  J Neurooncol       Date:  2016-02-20       Impact factor: 4.130

Review 2.  The Role of Metabolic Plasticity in Blood and Brain Stem Cell Pathophysiology.

Authors:  Catherine J Libby; Jonathan McConathy; Victor Darley-Usmar; Anita B Hjelmeland
Journal:  Cancer Res       Date:  2019-10-01       Impact factor: 12.701

Review 3.  Molecular imaging of brain tumors with radiolabeled choline PET.

Authors:  Ferdinando Franco Calabria; Manlio Barbarisi; Vincenzo Gangemi; Giovanni Grillea; Giuseppe Lucio Cascini
Journal:  Neurosurg Rev       Date:  2016-05-26       Impact factor: 3.042

Review 4.  Follow-Up Imaging: Molecular Imaging is Likely Best as a Single Modality, but Multimodality Imaging is the Future.

Authors:  Stephen Chiang
Journal:  Front Neurol       Date:  2015-04-24       Impact factor: 4.003

Review 5.  Accuracy of 11C-choline positron emission tomography in differentiating glioma recurrence from radiation necrosis: A systematic review and meta-analysis.

Authors:  Liansheng Gao; Weilin Xu; Tao Li; Jingwei Zheng; Gao Chen
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.